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Abstract: We report a last-step fluorinase catalyzed [18F]-
fluorination of a cysteine-containing RGD peptide. The peptide 
was attached through sulfur to a modified and more hydrophilic 
variant of the recently disclosed Barbas linker which was itself 
linked to a chloroadenosine moiety via a PEGylated chain. The 
fluorinase was able to use this construct as a substrate for a 
transhalogenation reaction to generate [18F]-radiolabelled RGD 






During the past decade, bioactive peptides, in particular 
cyclic RGD peptides, have been increasingly identified as 
targets for radiolabeling as positron emission tomography 
(PET) tracers due to their high target-selectivity, non-
immunogenicity, good tissue penetration and rapid 
metabolic clearance.1,2 Fluoride [18F] is the isotope of choice 
for PET as it has a moderate to long half-life (109.8 min) 
and is amenable to relatively extended synthesis and 
preparative manipulations. It also has a high percentage of 
β+ decay (97%) and a low β+ energy (635 Kev) and therefore 
a short positron range (2.3 mm in water). This leads to 
increased image resolution. Also the ease of production of 
[18F] at nM levels and in high specific activity by proton 
(H+) bombardment of an [18O]H2O target on a cyclotron,  
provides a ready source of the isotope in radiochemistry 
laboratories, particularly within hospital environments. 
[18F]Fluorination of peptides and other biomolecules is 
usually achieved by conjugation with small [18F]-labelled 
prosthetic synthons through complimentary 
functionalization. The most frequently employed small [18F] 
molecules are prepared by nucleophilic [18F]fluoride 
chemistry to generate 18F-C bonds. These include 
[18F]fluorobenzaldehyde ([18F]-FB)3,4 which is generally 
conjugated to aminoxy or hydrazine-decorated peptides via 
oximation or hydrazone formation, [18F]-fluorobenzoate 
([18F]-FBA)5 or N-succinimidyl 4-[18F]-fluorobenzoate 
([18F]-SFB)6 for reaction with the Nα-amino group of the 
backbone or Nε-amino group of  lysine residues by acylation 
or amidation, N-(2-[4-
[18F]fluorobenzamido]ethyl)maleimide ([18F]FBEM)7 which 
covalently modify at cysteine RSH residues, and [18F]azide 
or [18F]alkyne substrates8,9 which combine with alkyne or 
azide modified peptides via “click” reactions. The aldehyde 
form of the sugars 2-deoxy-2-[18F]fluoro-D-glucose 
([18F]FDG)10 and 5-deoxy-5-[18F]fluoro-D-ribose 
([18F]FDR)11,12 have also been used for aminooxy group 
conjugation to peptides and have some advantage in that 
they display increased hydrophilicity and a favorable 
radiopharmacokinetic profile. Also a new prosthetic group, 
4-[18F]fluorophenylboronic acid ([18F]FPB)13 was developed 
for Suzuki coupling with aryliodide derivatives of 
biomolecules.  
    While the best coupling reactions between the [18F] 
prosthetic group and peptides are mild, biorthogonal and 
site-specific, the syntheses of the [18F]-building blocks 
requires pre-drying of the [18F]fluoride, which is generated 
from [18O]H2O. Good nucleophilic reactions require 
anhydrous solvents to ensure fluoride nucleophilicity. This 
can often require harsh conditions incompatible with 
peptides, such as elevated temperatures. Therefore, a last-
step [18F]fluorination of a substrate under ambient aqueous 
conditions is attractive for radiosynthesis and is a current 
research focus within the radiochemistry community. To 
this end [18F]-fluoride has been reacted in last-step protocols 
with organosilicon decorated peptides to give [18F-SiFA]-
conjugate via 18F-19F isotopic exchange.14,15 Similarly, 
arylfluoroboronate modified peptides have been induced to 
capture carrier-added [18F]-fluoride under aqueous acidic 
condition in a single step to generate [18F]-ArBF3-
peptides.16,17 Alternatively [18F]fluoride can be locked into 
chelator (NODA or NOTA) functionalized peptides by 
coordination  chemistry with Al3+ as a last step treatment, to 
generate Al-[18F] tracers.18,19  
    Our focus has been on enzymatic incorporation of [18F] 
into candidate radiotracers under ambient conditions. The 
fluorinase enzyme, originally isolated from Streptomyces
cattleya, catalyzes the conversion of S-adenosyl-L-
methionine (AdoMet) and fluoride ion to 5ʹ-fluoro-5ʹ-
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deoxyadenosine (5ʹ-FDA) and L-methionine (L-Met).20 
Fluorinase also functions as a chlorinase, particularly in the 
reverse direction.21 The reversibility allows 5ʹ-chloro-5ʹ-
deoxyadenosine (5ʹ-ClDA) to be used as a substrate for 
fluorination in a one step reaction via AdoMet under 
ambient (pH 7.8 phosphate buffer, 37°C) aqueous conditions 
(Scheme 1).  
The reaction benefits from the fact that the equilibrium 
favors 5ʹ-FDA in fluorination but AdoMet in chlorination. In 
addition, the use of L-selenomethione (L-SeMet) in place of 
L-Met increases the reaction rate and improves the 
efficiency of the transhalogenation of (5ʹ-ClDA) to FDA. 
Fluorinase displays a high substrate specificity,  however, 
we have recently demonstrated that the introduction of an 
acetylene group at C-2 of the adenine base of 5ʹ-ClDA is 
tolerated by the enzyme.22 In addition this acetylene can be 
extended at its terminus to carry a pegylated cargo. 
Decoration of 5ʹ-ClDA in this way has allowed 
bioconjugation through “click” chemistry with azido 
functionalized peptides. In this context we have reported a 
‘last-step’ enzymatic [18F]fluorination of a 5ʹ-ClDA- RGD 
peptide conjugate with the fluorinase.22 This approach was 
good for lysine modified azido containing RGD peptides. It 
became an objective to develop a protocol compatible with 
cysteine ligation due to the general importance of cysteine in 
bioconjugation, often through an engineered cysteine thiol. 
A successful strategy would significantly broaden the utility 
of the enzymatic methodology for radiolabeling peptides 
and proteins. Conventional site-specific conjugates of 
cysteine with maleimide suffer from degradation via retro-
Michael reaction, and competition from thio-containing 
peptides or proteins such as glutathione or serum albumin 
present in vivo. 23     
Barbas and coworkers recently introduced methylsulfonyl 
oxadiazole for bioconjugation through nucleophilic aromatic 
substitution by cysteine residues to generate a relatively 
stable oxadiazole-protein thiolate.24,25 We saw an 
opportunity for combining this Barbas linker with our 
fluorinase technology in order to generate a thiol ligated 
peptides for last step enzymatic 18F-fluorination under 
ambient aqueous condition (Scheme 2).  
 
 
Scheme 1.  Fluorinase catalyzed fluorination and chlorination of AdoMet as well as the conversion of 5ʹ-ClDA to 5ʹ-FDA.  
 
 
Scheme 2.   Design of three components for last-step [18F] labelling of cysteine containing peptide: fluorinase substrate, 
Barbas linker and the cysteine-containing peptide. 
 
Results and Discussion 
RGD conjugation to a chlorodeoxyadenosine through 
modified Barbas linkers 
To obtain the conjugate, we attempted to click ClDA-
TEG 2 and 2-methylsufonyl 5-(4-
azidotetraethyleneglycoxyphenyl) oxadiazole 1a23 in the 
first step, but the free methylsulfonyl moiety was gradually 
hydrolysed during work up and this was not progressed. 
However when the sequence was reversed (Scheme 3) by 
first reacting the methylsulfonate 1a with the RGD, then the 
azido phenyl oxadiazole thiolate (APOT-RGD) 3a was 
obtained in excellent yield. 
    Conjugate 3a is very insoluble in common solvents 
such as MeOH, CH3CN and H2O and was only partially 
soluble in DMSO. A dilute solution of conjugate 3a in 
DMSO/H2O with ClDA-TEG-acetylene 222 under Cu 
catalyzed “click” conditions generated ClDA-APOT-RGD 
(4a), which was purified by semi-preparative HPLC. Again, 
ClDA-APOT-RGD (4a) is insoluble in common solvents 
with only partial solubility in DMSO.  
    To improve the solubility, a second PEGylated chain 
was introduced at the 3-position on the phenyl ring of the 
Barbas linker. This involved the selective deacylation and 
Williamson etherification at C-4 of the precursor benzoate 




Scheme 3.  Successive conjugation of methylsulfonyl azido phenyloxadiazole, RGD and ClDA-TEG or FDA-TEG and 
fluorinase catalyzed transhalogenation. Regents and conditions: a) c(RGDfC), PBS buffer (pH 7.4), 2 h; b) Compound 2, 
CuTBTA in 55% DMSO, sodium ascorbate, H2O, overnight; c) KF, L-SeMet, fluorinase, phosphate  buffer (pH 7.8). 
 
in a one pot protocol to give 7b (SI Scheme S1).26,27 Further 
etherification of 3-OH with tosylate 13 afforded 8b. Product 
8b was condensed with hydrazine and then cyclized with 
carbon disulfide in the presence of KOH to generate 
oxadiazole 10b.  Finally thiol methylation and then 
oxidation with m-CPBA gave bisPEGlated azido 
phenyloxadiazole 1b (SI Scheme S1).24 
    Conjugation of 1b with c(RGDfC) as shown in Scheme 
3 afforded 3b (MAPOT-RGD), and this construct was 
“clicked” with 2 affording (ClDA-MAPOT-RGD) 4b. The 
solubility of 4b was not significantly improved relative to 4a 
particularly in acetonitrile, methanol, ethanol and water.  
   There was the option of introducing a second 
PEGylated chain at C-5 of the phenyl ring, however the 
molecular weight of the construct is getting large, and 
therefore it seemed more appropriate to explore the free 
diphenol 4c as a potentially more soluble construct. The 
settled route to the analogous precursor 1c is shown in 
supporting information (SI Scheme S2).  Thiol conjugation 
of 1c with peptide c(RGDfC) in THF/phosphate buffer 
afforded 3c, which was then “clicked” with 2 under standard 
Cu catalyzed conditions to give 4c (Scheme 3). It is 
immediately apparent that 3c and 4c have increased 
solubility in MeOH and CH3CN relative to 3a/b and 4a/b.  
They have moderate water solubility (up to 0.1 mM for 4c). 
The increased solubility of 3c/4c makes them easier to 
handle and they do not require DMSO-d6 for 
characterization. 
The increased polarity and hydrophilicity of 4c is also 
reflected in reverse phase HPLC profiles. While 4a and 4b 
have almost the same retention time, 4c elutes over 1 min 
earlier than 4a and 4b under the conditions (Figure 1). 
 
   Figure 1. Comparative HPLC traces to illustrate the 
relative polarities of 4a (least polar), 4b, 4c and 4d (most 
polar) by retention time (mins). For HPLC conditions see 
Experimenal. 
   
   Simultaneously a variant of the Barbas linker was 
prepared without an aryl ring to explore solubility. Thus 
methylsulfonyl oxadiazole (1d) became a synthesis target 
(SI Scheme S3). A key reaction involved nucleophilic 
substitution of the methylsulfonate 1d with the thiol of 
(RGDfC) and this led to azido oxadiazole thiolate (AOT-
RGD) 3d. ‘Click’ reaction of 3d with 2 gave conjugate 
ClDA-AOT-RGD (4d) (Scheme 4).  
The solubility of 4d in water is significantly increased (2.3 
mM) relative to 4c (0.1 mM). Compounds 4a and 4b, are 
essentially insoluble. Reverse phase HPLC retention times 
were used as a proxy measure of solubility/polarity and 4d 
and then 4c eluted most rapidly as illustrated Figure 1. 
    The corresponding fluorinated conjugates 5a/b/c/d 
were prepared from reactions of 3a/b/c/d and FDA-TEG 
1522 (SI  Schemes S4 and S5). 





Scheme 4. Preparation of water soluble fluorinase substrate ClDA-AOT-RGD.  Reagents and conditions:  a) c(RGDfC), 
PBS buffer (pH 7.4), 2 h; b) Compound 2, CuTBTA in 55% DMSO, sodium ascorbate, H2O, 12 h; c) KF, L-SeMet, 
fluorinase, phosphate buffer (pH 7.8). 
 
‘Cold’ enzymatic fluorination of 4a/b/c/d to 5a/b/c/d 
    Non-radiolabelled fluorinase reactions (last step in 
Scheme 3 and 4) were generally performed in phosphate 
buffer (pH 7.8, 20 to 50 mM) at 37°C with the appropriate 
5’-chloro-5’-deoaxyadenosine substrate (0.1 mM), L-SeMet 
(0.1 mM), fluorinase (1 mg/mL) and potassium fluoride (75 
mM). For 4a, DMSO 5% v/v was added for solubility, 
although DMSO is detrimental to enzyme activity and 
promotes gelling on heat denaturation of the enzyme on 
workup. The enzymatic conversion of 4a proved sluggish 
(SI Figure S1) and did not improve for 4b with the added 
PEG chain (SI Figure S2). 
Constructs 4c (up to 0.1 mM) and 4d (up to 2.3 mM) had 
improved water solubility, and reactions were carried out in 
phosphate buffer (pH 7.8, 50 mM) without added DMSO. 
Workup of the neat aqueous reaction mixture was more 
straightforward than that for 4a and 4b which contained 
DMSO. The fluorinase enzyme was cleanly precipitated on 
heating at 95°C for 5 min and could be readily centrifuged 
(13000 rpm/5 min). 
The biotransformations of 4c to 5c and 4d to 5d (Figure 
2) are more efficient than that of 4a and 4b (SI Figure S1 
and S2). Substrate 4d was processed most efficiently and at 
about twice the rate of substrates 4a/b/c. An additional 
HPLC peak (at 16.1 min in Figure 2A and 14.9 min in 
Figure 2B) was attributed to a decomposition product 
associated with the AdoSeMet intermediate of the 
transhalogenation reactions based on MS analysis 
(exampled by SI Figure S3). 
 
Enzymatic hot [18F]fluorination of 4a/b/c to 5a/b/c 
For hot labelling, the [18F]fluoride is generated in GBq 
and used in MBq aliquots for reactions. The actual 
[18F]fluoride concentration is very low in the picomolar 
range but the enzyme is in excess in the micromolar range 
and therefore the reactions are no longer catalytic.   
 
Figure 2. HPLC traces monitoring fluorinase catalyzed 
conversions (%) of A; 4c (tR 15.7 min) to 5c (tR 14.9 min) 
via AdoSeMet intermediate (tR 16.1 min). B; 4d (tR 14.4 
min) to 5d (tR 13.4 min) via AdoSeMet intermediate (tR 
14.9 min). For full conditions see Experimental and SI 
Figure 1S and 2S). 
 
This stoichiometry is dramatically reversed relative to the 
cold reactions which use a large molar excess of fluoride 
over enzyme. The very low [18F] concentration requires a 
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high substrate concentration, and the low solubility of 4a and 4b in 5% DMSO limited their reaction concentrations to 
0.15 mM and 0.48 mM respectively. The conversion of 18F- 
into 5a and 5b was only modest (SI Figure S4 and S5, based 
on the integration of the peaks of product and unreacted 18F- 
ion by HPLC28). Substrate 4d, has good solubility but 
proved to be hydrolytically unstable (Figure 1, bottom 
HPLC trace shows a degraded product at 13.2 min) relative 
to 4a/b/c, and 5d visibly decomposed on work up, therefore 
radiochemical trials were not explored further with this 
substrate. 
   Substrate 4c has good solubility in water/DMSO and an 
efficient transhalogenation of 4c (reaction conc. ≤0.66 mM) 
to [18F]5c (final conc. of DMSO 2%, SI Figure S6) was 
accomplished (87% by HPLC)28. At 2% DMSO, the enzyme 
precipitated cleanly after heat denature without gel 
formation. The semi-prep HPLC purified [18F]5c was 
diluted with water and then secured on a C18 reverse phase 
cartridge. The product was finally eluted with EtOH (Figure 
3, SI Figure S7) for bioaffinity experiment. The total 
procedure from [18F]fluoride (422 MBq) to EtOH elution of 
[18F]5c  (22.5 MBq) took 1.5 h, and with a radiochemical 
yield of 5% (decay uncorrected).   
 
 
Figure 3. Analytical HPLC radio trace of purified 
[18F]5c. For full conditions see experimental and SI Figure 
S7 
 
Bioactivity of FDA-AOT-RGD conjugate 5a/b/c 
Bioaffinity assays were conducted on cell lines 
expressing αvβ3 integrins. The inhibitory concentrations 
(IC50’s) for 5a-c, competing with a biotinylated peptide 
binding to immobilized αvβ3 integrins were explored. This is 
a proxy measure of binding affinity to αvβ3 integrins on the 
surface of cancer cells. The IC50’s were compared with that 
of the cyclic peptide, cRGDfC (85.0 nM). The values, 5a 
(IC50 85.9 ± 50.2 nM), 5b (IC50 80.1 ± 14.2 nM) and 5c 
(IC50 177 ± 23 nM) proved to be similar, indicating that 
modification of RGD peptide with the 
fluoroadenosine/Barbas linker construct does not 
significantly affect its binding affinity. 
Binding of [18F]5c to αvβ3 integrins in cancer cells was 
evaluated in U87MG and PC3 cells, which are known to 
express high and medium levels of receptor.[29] Binding of 
[18F]5c to U87MG cells was higher than to PC3 cells. Cold 
c(RGDfK) (10 µM) was included in the binding assay to 
permit identification of specific radiotracer binding to αvβ3 
integrin (decreased by c(RGDfK). Inclusion of cold peptide 
decreased [18F]5c binding to both U87MG and PC3 cells by 
approximately 75% and 50% respectively (Figure 4). These 
data are consistent with the literature[29]  and flow cytometry 
analysis which demonstrated that our U87MG cells 
contained 9 times more αvβ3 than PC3 (data not shown). 
This data provide strong evidence that [18F]5c is binding 




Figure 4. Bound [18F]5c (cpm/mg) protein/MBq 
radiotracer 
Conclusions 
we have modified a cysteine-containing RGD peptide with a 
fluorinase-recognised chloroadenosine for fluorinase 
mediated radiolabelling with the fluorine-18 isotope. The 
recently introduced Barbas bioconjugation strategy was 
variously modified to improve solubility. The diphenol 4c, 
which derived from the sulfonyl oxadiazole 1c,  proved to 
be the most soluble construct and performed best for 
enzymatic mediated transhalogenation to generate 
radiolabelled [18F]5c.  Sulfonyl oxadiazole 1c may find 




Bioconjugation of Barbas linker with c(RGDfC) 
Compound 1a-d (1.5-4 eq.) in THF (400 ul) was added to 
a suspension of c(RGDfC) (1 eq) in  in PBS buffer (200 µL, 
100 mM, pH 7.4). The mixture was stirred at rt for 0.5-2 h 
and then concentrated under reduced pressure to remove the 
organic solvent, leaving an aqueous suspension containing 
product and excess of starting material. The excess 1a-d was 
removed effectively by extraction with diethyl ether; the 
aqueous suspension was dissolved / diluted with 
H2O/DMSO and purified by semi-preparative HPLC to give 
3a-d. 
 
‘Click’ reaction of 3a-d with 2 or 15 for 4a-d or 5a-d 
ClDA-TEG 2 or FDA-TEG 15 (1.2-2.0 eq) in suitable 
amount of water was added to 3a-d (1 eq) in suitable 
amount of DMSO. Sodium ascorbate (fresh aqueous 
degassed solution 100 mM or solid, 2-5 eq) was added to the 
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mixture. The mixture was degassed with argon before 
CuTBTA (10 mM in 55% DMSO, 0.2-0.5 eq) was added. 
The mixture was heated at 60°C for 10 min and stirred at RT 
overnight. After dilution with suitable amount of 
DMSO/H2O, the mixture was centrifuged at 13000 rpm for 
10 min to remove the Cu(I) precipitate. The supernatant was 
isolated by semi-preparative HPLC to give the product 4a-d 
or 5a-d after concentration and freeze drying. 
 
Fluorinase assay of 4a-c to 5a-c  
In a total reaction volume of 200 µL, recombinant 
fluorinase (1 mg.mL-1, in  phosphate buffer) was incubated 
with L-SeMet (0.1 mM), KF (75 mM) and 4a (0.1 mM)  or  
4b (0.1 mM)  in 5% DMSO/phosphate buffer (pH 7.8, 50 
mM) or 4c or 4d (0.1 mM) in phosphate  buffer (pH 7.8, 50 
mM) at 37 °C. Samples (20 µL) were periodically removed, 
denatured by heating at 95°C for 5 min, diluted with 
phosphate buffer (80 µl, 20 mM) before being clarified by 
centrifugation (13 000 rpm, 10 min). Samples of the 
supernatant (80 µL) were removed for analysis by HPLC. 
HPLC analysis (Figure 2 and SI Figure S2-3) was performed 
on a Shimadzu Prominence HPLC system fitted with a SIL-
20A HT autosampler, LC-20 AT solvent delivery system, 
SPD-20 UV/vis detector using a Phenomenex Luna 5 µm, 
C-18 100A (250 × 4.6 mm) column and a guard cartridge. 
Mobile phase: 0.05% TFA in water (solvent A) and 0.05% 
TFA in acetonitrile (solvent B); Linear gradient: 20-50% B 
in 20 min, 95% B in 25 min followed by equilibration of the 
column with initial condition; Flow rate of 1 mL.min-1; 
Detection: 254 nm; Injection volume: 50 µL.  
 
[18F] Labelling of 4a-c to [18F]5a-c  
    The typical 18F- labelling of 4 is exampled with 4c: L-
selenomethionine (40 µl), phosphate (50 mM, 30 µl) and 
fluorinase (5 mg in 50mM phosphate buffer, 125 µL) were 
added successively to an eppendorf containing substrate of 
4c (5 µl, 33 mM in DMSO). The contents were mixed well 
with pipette. To this mixture was added 50 µl of 
[18F]fluoride in [18O]-water (380 MBq). The contents were 
well mixed and incubated at 37 °C for 30 min. After this 
time, an aliquote of sample (20 µL) was taken for HPLC 
analysis. Once the conversion of 4c to [18F]5c was 
confirmed by the analysis, the remaining mixture was 
denatured by heating at 95 °C for 5 min and the precipitated 
protein was removed by centrifugation (13,000 rpm, 5 min). 
The supernatant was injected into a Shimadzu Prominence 
HPLC system equipped with a quaternary pump, a degasser, 
a flow cell detector and a diode array detector using a 
Phenomenex Luna 5 µm, C-18 100A (250 × 10 mm) column 
and a guard cartridge; Mobile phase: 0.05% TFA in water 
(solvent A) and 0.05% TFA in acetonitrile (solvent B); 
Linear  gradient: 0-4 min, 0%B, 4-10 min, 30%, 10-25 min 
33%, 28 min 90%B, 35 min 0%B, 40 min stop. Flow rate: 4 
mL. min-1. The radio-active fraction corresponding to the 
reference of [18F]5c was collected, diluted with water (10 
mL) and loaded onto a pre-activated Waters Oasis® HLB 
Cartridge (conditioning with 2 mL EtOH, 5 mL water). The 
cartridge was washed with 20 mL of water. The desired 
product was collected eluting with 1 mL of ethanol, giving 
ca 22.5 MBq (5%, decay uncorrected) of pure product of 
[18F]5c as evidenced by analytical HPLC using a 
Phenomenex Luna 5 µm, C-18 100A (250 × 4.6 mm,5µ) 
column and a guard cartridge; Mobile phase: A (H2O + 
0.05% TFA), B (MeCN + 0.05% TFA); Linear gradient: 0-4 
min 0% B, 4-10 min 0-30%B, 10-25 min 30-33%B, 25-30 
min 33-90%B, 30-35 min 0%B, 40 min stop. Flow rate: 1.0 
mL/min. 
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